Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results deaths Eclinical improvement Edeath or ventilation E

COVID-19 mild to moderate meta-analysis

Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020
 
NCT04322123
RCThydroxychloroquinestandard of careCOVID-19 mild to moderatesome concern
221/227 safety concern 42%
HC-nCoV (Shanghai), 2020
 
NCT04261517
RCThydroxychloroquinestandard of careCOVID-19 mild to moderatesome concern
15/15 inconclusive 0%
NCT04333654, 2020
 
NCT04333654
RCThydroxychloroquinestandard of careCOVID-19 mild to moderateNA
-/- inconclusive -40%
Zhaowei Chen, 2020
 
ChiCTR2000029559
RCThydroxychloroquinestandard of careCOVID-19 mild to moderatehigh
31/31 suggested 219%
Zhaowei Chen, 2020
 
ChiCTR2000029559
RCThydroxychloroquinecontrolCOVID-19 mild to moderatehigh
31/31 inconclusive 0%
Min, 2020 OBShydroxychloroquinecontrolCOVID-19 mild to moderateNA
20/20 inconclusive

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).